Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda Pharmaceuticals UK said Axorid, which is indicated to prevent arthritis sufferers from developing fatal gastric bleeding, has received an extension of its license.
Subscribe to our email newsletter
The new license means that Android is now available for the symptomatic treatment of rheumatoid arthritis, osteoarthritis or ankylosing spondylitis.
Axorid, which is to be taken as a daily capsule, provides pain relief as well as protection to the stomach in a single pill, Meda Pharma said.
Axorid contains a painkiller and protective omeprazole, which reduces levels of stomach acid.
Reportedly, it is the first medicine to combine a non-steroidal anti-inflammatory treatment (NSAID) with a proton pump inhibitor, to offer protection from stomach ulcers and gastric bleeding.
National Rheumatoid Arthritis Society spokeswoman Lynn Love said a drug that combines a non-steroidal anti-inflammatory with stomach protection will help some people with arthritis especially those that take a lot of different tablets and can be confused about what to take and when.